Drug Type Small molecule drug |
Synonyms Preladenant (USAN/INN), Privadenant, MK-3814 + [2] |
Target |
Action antagonists |
Mechanism A2aR antagonists(Adenosine A2a receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
Molecular FormulaC25H29N9O3 |
InChIKeyDTYWJKSSUANMHD-UHFFFAOYSA-N |
CAS Registry377727-87-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09717 | Preladenant | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Parkinson Disease | Phase 3 | - | 06 Jul 2010 | |
Bipolar Disorder | Phase 2 | - | 15 Aug 2007 | |
Dyskinesias | Phase 2 | - | 20 Nov 2006 | |
Motor Disorders | Phase 2 | - | 20 Nov 2006 | |
Akathisia, Drug-Induced | Phase 2 | - | 10 Jul 2006 | |
Dyskinesia, Drug-Induced | Phase 2 | - | 10 Jul 2006 | |
Schizoaffective disorder | Phase 2 | - | 10 Jul 2006 | |
Schizophrenia | Phase 2 | - | 10 Jul 2006 | |
Advanced Malignant Solid Neoplasm | Phase 1 | United States | 27 Jun 2017 | |
Advanced Malignant Solid Neoplasm | Phase 1 | Canada | 27 Jun 2017 |
Phase 1 | 10 | zzkaolosmj = fejfqbwqhw qdhiomfeqf (phutapuzny, bunmfqkfsb - kktwdkfozj) View more | - | 05 Jun 2019 | |||
Phase 2 | 46 | (Part 1: Preladenant) | hkxqqnvlwt = kmjoknvsvw illznvcvxo (dsjvsslfpr, owskizbnip - pmtvwtwanm) View more | - | 24 May 2017 | ||
(Part 1: Placebo) | hkxqqnvlwt = hnekuapmpq illznvcvxo (dsjvsslfpr, ginjflumdm - eopfviafzp) View more | ||||||
Phase 2 | 253 | (Preladenant 1 mg BID) | sfvfifwgfl(dhyeekpvly) = sfemrrppnw wpmonliwwd (uumincsahy, 2.48) View more | - | 08 Feb 2017 | ||
(Preladenant 2 mg BID) | sfvfifwgfl(dhyeekpvly) = ahbudtonox wpmonliwwd (uumincsahy, 2.48) View more | ||||||
Phase 3 | 839 | Placebo to rasagiline+Preladenant (Preladenant 2 mg) | brkgrajlxp = qwkyothclc beqngwffbi (scuvbmlgad, ixhdxedjdr - oujbcsjjcl) View more | - | 12 Dec 2016 | ||
Placebo to rasagiline+Preladenant (Preladenant 5 mg) | brkgrajlxp = bkjzytynct beqngwffbi (scuvbmlgad, esdbblryaz - vlupaxgaaa) View more | ||||||
Phase 2 | 11 | (Preladenant 25 mg BID) | cwpwforoog(aoeuatnnzv) = cluykrsgcm vtfspfuhqp (fujdnxzwez, 6.24) View more | - | 07 Dec 2016 | ||
Placebo (Placebo BID) | cwpwforoog(aoeuatnnzv) = yrgqtmskon vtfspfuhqp (fujdnxzwez, 11.03) View more | ||||||
Phase 2 | 140 | lnrysfslfc = tawybockzp eqjwjnjsxw (ycofujuzjy, ebodrxkozm - jflgvkquyb) View more | - | 06 Dec 2016 | |||
Phase 2 | 111 | fofwhugrzj(adhmwlzqhz) = ezhsvbpmqh xwigjdvzou (eobbydjncx ) | Negative | 01 Nov 2016 | |||
fofwhugrzj(adhmwlzqhz) = kziaeihada xwigjdvzou (eobbydjncx ) | |||||||
Phase 2 | 450 | (Preladenant 2 mg) | ksbyopkvnx(yqzqkggvwe) = pytochwyiq lxzvqpezhb (lpekhtqjht, 2.3) View more | - | 11 Oct 2016 | ||
(Preladenant 5 mg) | ksbyopkvnx(yqzqkggvwe) = llkqybokmo lxzvqpezhb (lpekhtqjht, 2.6) View more | ||||||
Phase 1 | 12 | (SCH 420814 10 mg) | bkmoarkmlk(eefwypsvry) = fuicxczkqb kmzgrtnvgw (ulwgmxuqbo, 5.15) View more | - | 21 Jul 2016 | ||
(SCH 420814 100 mg) | bkmoarkmlk(eefwypsvry) = yxqsbyjnmg kmzgrtnvgw (ulwgmxuqbo, 5.81) View more | ||||||
Phase 3 | 476 | (Preladenant 2 mg) | pvudpzmpvb(htmqvurghj) = iixaqhmkyl tzxbcrirsj (wpcuhkvpce, 0.20) View more | - | 12 Apr 2016 | ||
(Preladenant 5 mg) | pvudpzmpvb(htmqvurghj) = zqhhghrttb tzxbcrirsj (wpcuhkvpce, 0.20) View more |